Predictors for AKI
The Kaplan–Meier analysis revealed that a higher eGFR (HR: 1.02 [1.00–1.04]) and blood eosinophil count >350/μL (HR: 4.3 [1.21–15.25]) were associated with a higher risk of AKI during anti-TB treatment. Other risk factors, such as BMI, smoking status, hypertension, diabetes mellitus, mycobacterial culture results (a positive AFB smear or positive TB culture), other baseline laboratory data, and treatment-related side effects, were not statistically significant (Table 4).
The multivariate Cox regression analysis revealed that older age (HR: 1.06 [1.02–1.11]), a higher baseline eGFR (HR: 1.04 [1.02–1.06] per unit increase in eGFR), and a blood eosinophil count >350 (109/L) (HR: 10.99 [1.28–53.02]) were significant predictors for AKI development during anti-TB treatment (Table 4).